Alvotech And Dr Reddy's Partner To Commercialize Denosumab Biosimilar

Dr. Reddy's Laboratories and Alvotech partnered to make denosumab biosimilar accessible in the US, Europe, and UK. The partnership will provide an access to a potentially more affordable treatment option for patients.

Global biotech company, Alvotech and a subsidiary of Dr. Reddy's Laboratories makes an announced on Tuesday that they have entered into a license and supply agreement to commercialize AVT03, a biosimilar candidate to Prolia and Xgeva (denosumab).

As per the press release from Dr. Reddy's, the collaboration leverages Dr. Reddy's extensive global commercial presence and Alvotech's expertise in developing biosimilars for international markets.

AVT03, a human monoclonal antibody, is biosimilar to Prolia and Xgeva, both forms of denosumab used for clinical indications. Prolia is commonly prescribed to treat osteoporosis in postmenopausal women, while Exgeva is used to prevent osteoporotic events in adults with advanced malignancies

Under the agreement, Alvotech will handle the development and manufacturing of AVT03, while Dr. Reddy's will be responsible for its registration and sales in the respective markets. The agreement also includes an upfront payment to Alvotech, with additional payments contingent on achievement of certain regulatory and commercialization milestones, as well as sales-based payments.

Dr. Reddy's will hold exclusive commercialization rights for the US market and semi-exclusive rights for Europe and the UK.

Erez Israeli, CEO of Dr. Reddy's, expressed excitement about the collaboration, highlighting the company's commitment to making the denosumab biosimilar available to patients in the US, Europe, and the UK. He noted that Dr. Reddy's has developed a portfolio of biosimilar products that are already being marketed in several emerging markets.

Robert Wessman, Chairman and CEO of Alvotech, echoed this sentiment, saying, "We are proud to announce this new strategic partnership that will enable us to increase the availability of cost-effective, critical biologic medications across multiple markets worldwide."